VYGR Relative Valuation
VYGR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VYGR is overvalued; if below, it's undervalued.
Historical Valuation
Voyager Therapeutics Inc (VYGR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.00. The fair price of Voyager Therapeutics Inc (VYGR) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：4.35
Fair
-2.28
PE
1Y
3Y
5Y
Trailing
Forward
-0.37
EV/EBITDA
Voyager Therapeutics Inc. (VYGR) has a current EV/EBITDA of -0.37. The 5-year average EV/EBITDA is -1.09. The thresholds are as follows: Strongly Undervalued below -10.52, Undervalued between -10.52 and -5.80, Fairly Valued between 3.63 and -5.80, Overvalued between 3.63 and 8.35, and Strongly Overvalued above 8.35. The current Forward EV/EBITDA of -0.37 falls within the Historic Trend Line -Fairly Valued range.
-0.31
EV/EBIT
Voyager Therapeutics Inc. (VYGR) has a current EV/EBIT of -0.31. The 5-year average EV/EBIT is 4.86. The thresholds are as follows: Strongly Undervalued below -43.31, Undervalued between -43.31 and -19.23, Fairly Valued between 28.94 and -19.23, Overvalued between 28.94 and 53.02, and Strongly Overvalued above 53.02. The current Forward EV/EBIT of -0.31 falls within the Historic Trend Line -Fairly Valued range.
5.66
PS
Voyager Therapeutics Inc. (VYGR) has a current PS of 5.66. The 5-year average PS is 10.85. The thresholds are as follows: Strongly Undervalued below -16.65, Undervalued between -16.65 and -2.90, Fairly Valued between 24.60 and -2.90, Overvalued between 24.60 and 38.34, and Strongly Overvalued above 38.34. The current Forward PS of 5.66 falls within the Historic Trend Line -Fairly Valued range.
-2.15
P/OCF
Voyager Therapeutics Inc. (VYGR) has a current P/OCF of -2.15. The 5-year average P/OCF is -4.38. The thresholds are as follows: Strongly Undervalued below -14.20, Undervalued between -14.20 and -9.29, Fairly Valued between 0.52 and -9.29, Overvalued between 0.52 and 5.43, and Strongly Overvalued above 5.43. The current Forward P/OCF of -2.15 falls within the Historic Trend Line -Fairly Valued range.
-2.10
P/FCF
Voyager Therapeutics Inc. (VYGR) has a current P/FCF of -2.10. The 5-year average P/FCF is -2.77. The thresholds are as follows: Strongly Undervalued below -22.22, Undervalued between -22.22 and -12.49, Fairly Valued between 6.96 and -12.49, Overvalued between 6.96 and 16.69, and Strongly Overvalued above 16.69. The current Forward P/FCF of -2.10 falls within the Historic Trend Line -Fairly Valued range.
Voyager Therapeutics Inc (VYGR) has a current Price-to-Book (P/B) ratio of 1.10. Compared to its 3-year average P/B ratio of 1.68 , the current P/B ratio is approximately -34.52% higher. Relative to its 5-year average P/B ratio of 1.87, the current P/B ratio is about -41.29% higher. Voyager Therapeutics Inc (VYGR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.45%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -19.05% , the current FCF yield is about -100.00% lower.
1.10
P/B
Median3y
1.68
Median5y
1.87
-50.54
FCF Yield
Median3y
-6.45
Median5y
-19.05
Competitors Valuation Multiple
The average P/S ratio for VYGR's competitors is 0.00, providing a benchmark for relative valuation. Voyager Therapeutics Inc Corp (VYGR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -45.73%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VYGR decreased by 23.28% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -36.72 to -208.69.
The secondary factor is the Revenue Growth, contributed -45.73%to the performance.
Overall, the performance of VYGR in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Voyager Therapeutics Inc (VYGR) currently overvalued or undervalued?
What is Voyager Therapeutics Inc (VYGR) fair value?
How does VYGR's valuation metrics compare to the industry average?
What is the current P/B ratio for Voyager Therapeutics Inc (VYGR) as of Dec 05 2025?
What is the current FCF Yield for Voyager Therapeutics Inc (VYGR) as of Dec 05 2025?
What is the current Forward P/E ratio for Voyager Therapeutics Inc (VYGR) as of Dec 05 2025?